Synthesis and p 38 Inhibitory Activity of Some Novel Substituted N , N 1-Diarylurea Derivatives

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod

  2015cited by this paper
• Design, Synthesis and Biological Evaluation of Novel Substituted N,N′-Diaryl ureas as Potent p38 Inhibitors

  2015cited by this paper
• Activation of the MAPK11/12/13/14 (p38 MAPK) pathway regulates the transcription of autophagy genes in response to oxidative stress induced by a novel copper complex in HeLa cells

  2014cited by this paper
• A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

  2014cited by this paper
• Selective catalytic transfer hydrogenation of nitriles to primary amines using Pd/C

  2014cited by this paper
• Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.

  2014cited by this paper
• Targeting angiopoietin-2 signaling in cancer therapy

  2013cited by this paper
• Signal transduction inhibitors in treatment of myelodysplastic syndromes

  2013cited by this paper
• Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial

  2013cited by this paper
• Vascular histomolecular analysis by sequential endoarterial biopsy in a shunt model of pulmonary hypertension

  2013cited by this paper
• Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.

  2012cited by this paper
• Design and synthesis of novel p38α MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety.

  2012cited by this paper
• Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.

  2011cited by this paper
• p38 mitogen-activated protein kinase pathways in asthma and COPD.

  2011cited by this paper
• Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

  2011cited by this paper
• Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation

  2011cited by this paper
• Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.

  2010cited by this paper
• Short Synthesis of 1-(3-tert-Butyl-1-phenyl-1H-pyrazol-5-yl)-3-(5-(2-morpholinoethoxy)-2H-chromen-8-yl) Urea Derivatives

  2009cited by this paper
• Signal integration by JNK and p38 MAPK pathways in cancer development

  2009cited by this paper
• Successful structure-based design of recent p38 MAP kinase inhibitors.

  2009cited by this paper
• Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition

  2008cited by this paper
• Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition

  2008influential reference
• Microwave-assisted synthesis of N-pyrazole ureas and the p38alpha inhibitor BIRB 796 for study into accelerated cell ageing.

  2006cited by this paper
• Rational design of inhibitors that bind to inactive kinase conformations

  2006cited by this paper
• Kinetic studies of small molecule interactions with protein kinases using biosensor technology.

  2005cited by this paper
• Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions.

  2005cited by this paper
• p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

  2003cited by this paper
• Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).

  2003cited by this paper
• Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

  2002cited by this paper
• The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.

  2002cited by this paper
• Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.

  2002cited by this paper
• Potential of p38 inhibitors in the treatment of rheumatoid arthritis.

  2000cited by this paper
• Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.

  1999cited by this paper
• Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

  1999cited by this paper
• A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

  1994cited by this paper

• No citing papers are available for this paper.